A Phase 1 Study of Valemetostat Plus Atezolizumab in People With Small Cell Lung Cancer

Full Title

Purpose

Atezolizumab is a standard treatment for extensive-stage small cell lung cancer (SCLC, cancer which has spread). Researchers want to see if adding valemetostat to atezolizumab therapy is safe for people with SCLC. The people in this study have extensive-stage SCLC and have completed 4 treatment cycles of atezolizumab with chemotherapy.

Valemetostat blocks proteins called EZH1 and EZH2. The proteins are found on cancer cells and play a role in cancer growth and survival. By blocking these proteins, valemetostat may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Atezolizumab blocks a protein called PD-L1 that acts as a “brake” on the immune system. Blocking this protein is like releasing the brakes, so the immune system can find and kill cancer cells. Atezolizumab is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have extensive-stage SCLC and have completed 4 cycles of atezolizumab with chemotherapy.
• Have finished the last cycle of treatment within 4 weeks of starting the study therapy.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Charles Rudin’s office at 646-608-3788.